In vitro susceptibility of Aspergillus spp. to dithiocarbamate organoruthenium compounds

Mycoses

Volumn 54, Issue 5, 2011, Pages

  Nogueira, Luciano J ^a   de Resende, Maria A ^a   Oliveira, Sheila R ^a   de Araújo, Maria Helena ^a   Magalhães, Thais F F ^a   de Oliveira, Milena B ^a   Martins, Cleide V B ^a,b   Lopes, Miriam T P ^a   Araújo e Silva, Ana C ^a   Donnici, Claudio L ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

Author keywords

Amphotericin B; Antifungal susceptibility; Cytotoxicity testing; Dinuclear ruthenium complexes; Emerging infectious diseases; Fluconazole

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA PENTAKIS(N ISOPROPYLDITHIOCARBAMATE)DIRUTHENIUM; ALPHA PENTAKIS(N TERT BUTYLDITHIOCARBAMATE)DIRUTHENIUM; ALPHA PENTAKIS(N,N DIETHYLDITHIOCARBAMATE)DIRUTHENIUM; ALPHA PENTAKIS(N,N DIISOPROPYLDITHIOCARBAMATE)DIRUTHENIUM; ALPHA PENTAKIS(N,N DIMETHYLDITHIOCARBAMATE)DIRUTHENIUM; ANTIFUNGAL AGENT; DITHIOCARBAMIC ACID DERIVATIVE; RUTHENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS CLAVATUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS NOMIUS; ASPERGILLUS TAMARII; ASPERGILLUS TERREUS; ASSAY; CELL STRAIN BHK; CONCENTRATION RESPONSE; CYTOTOXICITY; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ASPERGILLUS; CELL LINE; CELL SURVIVAL; CRICETINAE; MICROBIAL SENSITIVITY TESTS; RUTHENIUM COMPOUNDS; THIOCARBAMATES;

ASPERGILLUS; ASPERGILLUS CLAVATUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS NOMIUS; ASPERGILLUS TAMARII; ASPERGILLUS TERREUS; FUNGI; MAMMALIA;

EID: 80052810009     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2010.01914.x     Document Type: Article

References (34)

1. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
2. Lai CC, Tan CK, Huang YT. Current challenges in the management of invasive fungal infections. J Infect Chemother 2008; 14: 77-85.
3. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16: 521-6.
4. Luna EJA. The emergence of emerging diseases and emerging and reemerging infectious diseases in Brazil. Rev Bras Epidemiol 2002; 5: 229-43.
5. Sundriyal S, Sharma RK, Jain R. Current advances in antifungal targets and drug development. Curr Med Chem 2006; 13: 1321-35.
6. Varga J, Rigó K, Tóth B, Téren J, Kozakiewicz Z. Evolutionary relationships among Aspergillus species producing economically important mycotoxins. Food Technol Biotechnol 2003; 41: 29-36.
7. Walsh TJ, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305-19.
8. Sridhar H, Jayshree RS, Bapsy PP et al. Invasive aspergillosis in cancer. Mycoses 2002; 45: 358-63.
9. Klock C, Cerski M, Dargel A, Goldani LZ. Case report. Disseminated aspergillosis complicating pregnancy. Mycoses 2002; 45: 408-10.
10. Berthet N, Faure O, Bakri A, Ambroise-Thomas P, Grillot R, Brugère JF. In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole. J Antimicrob Chemother 2003; 51: 1419-22.
11. Mellado E, Fuoli LA, Effron GG, Izquierdo AA, Estrella MC, Tudela JLR. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006; 44(Suppl. 1): 367-71.
12. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135-8.
13. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005; 55: 914-20.
14. Imai J, Singh G, Fernandez B, Clemons KV, Stevens DA. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2006; 56: 166-71.
15. Charvalos E, Tzatzarakis MN, Bambeke FV et al. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother 2006; 57: 236-44.
16. Biersack B, Diestel R, Jagusch C, Sasse F, Schobert R. Metal complexes of natural melophlins and their cytotoxic and antibiotic activities. J Inorg Biochem 2009; 103: 72-76.
17. 2 macrocyclic Schiff base ligands: their antibacterial and antifungal studies. Spectrochim Acta A 2009; 73: 205-11.
18. Ramesh R, Maheswaran S. Synthesis, spectra, dioxygen affinity and antifungal activity of Ru(III) Schiff base complexes. J Inorg Biochem 2003; 96: 457-62.
19. Zakeeruddin SM, Fraser DM, Nazeeruddin MK, Grätzel M. Towards mediator design: characterization of tris-(4, 4'-substituted-2, 2'-bipyridine) complexes of iron(II), ruthenium(II) and osmium(II) as mediators for glucose oxidase of Aspergillus niger and other redox proteins. J Electroanal Chem 1992; 337: 253-83.
20. Menezes DC, Vieira FT, de Lima GM et al. Tin(IV) complexes of pyrrolidine dithiocarbamate: synthesis, characterization and antifungal activity. Eur J Med Chem 2005; 40: 1277-82.
21. Menezes DC, Vieira FT, de Lima GM et al. The in vitro antifungal activity of some dithiocarbamate organotin(IV) compounds on Candida albicans- a model for biological interaction of organotin complexes. Appl Organometallic Chem 2008; 22: 221-6.
22. Klöpping HL, Van der Kerk GJM. Investigations on organic fungicides. Rec Trav Chim Pays-Bas 1951; 70: 917-39.
23. Arora A, Sud D, Sharma JR. Transition metal dialkyldithiocarbamates and their antifungal activity. Chem Asian J 2003; 15: 715-9.
24. De Vos D, Willem R, Gielen M, Van-Wingerden KE, Nooter K. The development of novel organotin anti-tumor drugs: structure and activity. Met Based Drugs 1998; 5: 179-88.
25. Brabec V, Nováková O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat 2006; 9: 111-22.
26. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. Wayner, PA: NCCLS, 2002.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival. J Immunol Methods 1983; 65: 55-63.
28. Kannan S, Sivagamasundari M, Ramesh R, Liu Y. Ruthenium(II) carbonyl complexes of dehydroacetic acid thiosemicarbazone: synthesis, structure, light emission and biological activity. J Organometallic Chem 2008; 693: 2251-7.
29. Anthonysamy A, Balasubramanian S, Shanmugaiah V, Mathivanan N. Synthesis, characterization and electrochemistry of 4'-functionalized 2, 2':6', 2″-terpyridine ruthenium(II) complexes and their biological activity. Dalton Trans 2008; 16: 2136-43.
30. Balloy V, Chignard M. The innate immune response to Aspergillus fumigates. Microbes Infect 2009; 11: 919-27.
31. Gafa V, Lande R, Gagliardi MC et al. Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response. Infect Immun 2006; 74: 1480-9.
32. Gallis HA, Drew RH, Picard WW. Amphotericin B: 30years of clinical experience. Rev Infect Dis 1990; 12: 308-29.
33. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulation and drug targeting. J Pharm Sci 2008; 97: 2405-25.
34. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal Amphotericin B): a comparative review. J Clin Pharmacol 1998; 38: 583-92.